Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) COO Melissa Baird sold 67,687 shares of the stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $44.71, for a total value of $3,026,285.77. Following the completion of the sale, the chief operating officer now owns 706,872 shares of the company’s stock, valued at approximately $31,604,247.12. This trade represents a 8.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Melissa Baird also recently made the following trade(s):
- On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.35, for a total value of $1,986,613.45.
- On Tuesday, December 10th, Melissa Baird sold 85,561 shares of Hims & Hers Health stock. The shares were sold at an average price of $31.01, for a total value of $2,653,246.61.
- On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00.
Hims & Hers Health Trading Up 2.1 %
Shares of NYSE HIMS opened at $60.41 on Friday. The company has a market cap of $13.20 billion, a price-to-earnings ratio of 137.31 and a beta of 1.35. Hims & Hers Health, Inc. has a 12-month low of $9.22 and a 12-month high of $64.84. The stock’s 50 day simple moving average is $32.06 and its 200 day simple moving average is $24.28.
Institutional Trading of Hims & Hers Health
Analyst Ratings Changes
A number of research analysts recently commented on HIMS shares. TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their price target for the company from $24.00 to $25.00 in a report on Friday, January 10th. Piper Sandler increased their price target on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Finally, Morgan Stanley started coverage on Hims & Hers Health in a report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $25.13.
Read Our Latest Stock Analysis on HIMS
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Further Reading
- Five stocks we like better than Hims & Hers Health
- How to Find Undervalued Stocks
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Market Cap Calculator: How to Calculate Market Cap
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.